A generic drug finished in an American factory but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine produced at two independent plants with multiple qualified suppliers.

That distinction matters as President Donald Trump moves to bring generic-drug manufacturing back to the United States. He has announced a plan to keep imported generics tariff-free until August 2028, before imposing steep tariffs intended to encourage domestic production.